Pharmaceutical company Biogen's share prices are increasing rapidly on the US stock exchange after the US health authority, the Food and Drug Administration (FDA), approved its Alzheimer's medication on Monday.
Biogen entered the stock exchange before the approval, and in the first minutes of trading after it was obtained, the share price rose by 58 percent to USD 452.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Head of Development Operations - Genmab 
Associate Medical Director, Clinical Development, Y-mAbs Therapeutics 
Senior Formulation Scientist, Oral Formulation Research - Novo Nordisk 
Regulatory affairs life cycle specialist 
Principal Biostatistician - ALK 
Employee for regulatory department 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen 
Senior CMC Expert/Senior CMC Project Manager - Klifo 
Clinical Supply Manager/Specialist - Lundbeck